Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
The price for the Pacira Pharmaceuticals stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.510%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Pacira Pharmaceuticals.
With a target price of 29 € there is a positive potential of 48.72% for Pacira Pharmaceuticals compared to the current price of 19.5 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -0.510% | -7.477% | -7.477% | 11.864% | -8.333% | -41.071% | -65.565% |
| Rockwell Medical Inc. | -0.650% | -5.576% | -1.316% | -60.860% | 16.408% | -46.062% | -92.089% |
| Twist Bioscience Corp | 1.260% | 11.475% | 23.824% | -25.377% | 17.199% | 33.224% | -75.642% |
| Vericel Corp. | -0.640% | 2.532% | 2.532% | -41.622% | 2.532% | 27.258% | 12.971% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat